Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Interest Expenses (2025)

Iovance Biotherapeutics (IOVA) has disclosed Interest Expenses for 3 consecutive years, with $13.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Interest Expenses changed N/A to $13.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $13.7 million, a N/A change, with the full-year FY2014 number at -$5660.0, down 101.27% from a year prior.
  • Interest Expenses was $13.7 million for Q3 2025 at Iovance Biotherapeutics, up from $477714.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $13.7 million in Q3 2025 to a low of $13.7 million in Q3 2025.